Caliper Life Sciences signs co-marketing pact with Illumina to improve sequencing workflows

Incorporation of analytical and preparative microfluidics solutions said to improve data quality and simplify next-generation sequencing sample preparation

Jeffrey Bouley
Register for free to listen to this article
Listen with Speechify
HOPKINTON, Mass.—Caliper Life Sciences Inc. has announced a co-marketing agreement with Illumina Inc. for Caliper's LabChip XT library preparation instrument and its LabChip GX analytical quality control platform—systems designed to be automated alternatives to traditional gel electrophoresis methods for next-generation sequencing library construction and assessment.

Lying at the heart of the agreement is the belief on the part of both companies that the LabChip platforms provide Genome Analyzer and HiSeq2000 users with more accurate and higher throughput solutions for sample analysis and sizing, significantly reducing manual manipulations while improving data quality and sample-to-sample consistency.

"Our preparative and analytical microfluidics technologies are uniquely positioned to provide the speed, accuracy, and sensitivity necessary to enable the growing applications of sequencing technologies," says Kevin Hrusovsky, president and CEO of Caliper. "The LabChip XT in particular was developed with direct input from Illumina and we are excited to enter into this co-marketing agreement to promote both LabChip products to address critical bottlenecks in sample preparation of next generation sequencing libraries."

The preparative LabChip XT reportedly removes a key bottleneck in sequencing library preparation by replacing tedious and inconsistent gel isolation steps, in part by using a multi-channel, disposable chip that fractionates up to four samples in less than 30 minutes. This novel design eliminates the potential for cross contamination, provides digital data for analysis and quantification, and offers an accuracy and consistency that Caliper and Illumina maintain was not previously possible.

Jeffrey Bouley

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue